Advertisement

Cefepime Injection

[24 June 2016]

Products Affected - Description

Maxipime powder for solution for injection, Hospira
1 gram, ADD-Vantage vial, 25 count (NDC 00409-0217-01)
1 gram, vial, 10 count (NDC 00409-0219-01)
2 gram, ADD-Vantage vial, 25 count (NDC 00409-0218-01)
2 gram, vial, 10 count (NDC 00409-0220-01)
 
Cefepime powder for injection, Apotex
1 gram, vial, 1 count (NDC 60505-0834-00)
1 gram, vial, 10 count, NDC 60505-0834-04)
2 gram, vial, 1 count (NDC 60505-0681-00)
2 gram, vial, 10 count (NDC 60505-0681-04)
 
Cefepime injection, BBraun
1 gram/50 mL, premixed bag, 24 count (NDC 00264-3193-11)
2 gram/100 mL, premixed bag, 24 count (NDC 00264-3195-11)
 
Cefepime injection, Baxter
2 gram/100 mL, premixed bag, 12 count (NDC 00338-1301-41)
2 gram/100 mL, premixed bag, 12 count (NDC 00338-1301-48)
 
Cefepime powder for injection, Fresenius Kabi
1 gram, vial, 10 count (NDC 63323-0326-20)
2 gram vial, 10 count (NDC 63323-0340-20)
 
Cefepime powder for solution for injection, Sagent
1 gram, vial, 10 count (NDC 25021-0121-20)
2 gram, vial, 10 count (NDC 25021-0122-50)
 
Cefepime powder for solution for injection, Sandoz
1 gram, vial, 10 count (NDC 00781-3222-95) - discontinued
2 gram, vial, 10 count (NDC 00781-3223-95) - discontinued
 
Cefepime powder for solution for injection, WG Critical Care
1 gram, vial, 10 count (NDC 44567-0240-10)
2 gram, vial, 10 count (NDC 44567-0241-10)

Reason for the Shortage

  • Apotex could not provide a reason for the shortage.
  • BBraun has cefepime on allocation due to increased demand.
  • Baxter has cefepime on shortage due to increased demand.
  • Fresenius Kabi has cefepime injection on shortage due to manufacturing delays.
  • Sagent has cefepime injection on shortage due to manufacturing delays.
  • WG Critical Care has cefepime injection on shortage due to increased demand.
  • Hospira has Maxipime on shortage due to manufacturing delays.
  • Sandoz discontinued cefepime injection in early 2016.

Available Products

There is insufficient supply for usual ordering.

Estimated Resupply Dates

  • Apotex has cefepime 2 gram vials in 1 count on back order and the company estimates a release date of mid-July 2016. All other presentations are on back order and the company cannot estimate a release date.
  • Braun has cefepime 1 and 2 gram premixed bags on allocation to contracted customers.
  • Baxter has cefepime 1 gram/50 mL and 2 gram/100 mL premixed bags on allocation.
  • Fresenius Kabi has cefepime 1 gram and 2 gram vials on back order and the company estimates a release date of 3rd quarter 2016 for the 1 gram vials and 2nd quarter 2016 for the 2 gram vials.
  • Hospira has Maxipime 1 gram vials available in limited supply. The 1 gram ADD-Vantage vials, 2 gram vials and 2 gram ADD-Vantage vials are on back order and the company estimates a release date of December 2016 for the 1 gram ADD-Vantage vials and 2 gram ADD-Vantage vials, and August 2016 for the 2 gram vials.
  • Sagent has cefepime 1 gram and 2 gram vials on back order and the company estimates a release date of July 2016.
  • WG Critical Care has cefepime 1 gram and 2 gram vials on back order and the company estimates a release date of late-July 2016 for the 2 gram vials and cannot estimate a release date for the 1 gram vials. Check wholesalers for availability.

Related Shortages

Updated

June 24 and 21, May 27, 26, 16 and 9, April 13 and 6, February 29, 26 and 2, January 14 and 12, 2016; December 23, 17, 16 and 11, November 3, October 20, September 23, 14 and 3, August 11, July 28 and 14, June 29, 17, 11, 8 and 3, May 21 and 12, April 17 and 3, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing